Articles Related to eGFR
Kidney Injury in Ordinary Adult Cases of Coronavirus Disease 2019
Kidney injury has been observed broadly in severe and critical coronavirus disease 2019 (COVID-19) patients, but the impairment of renal function in ordinary cases has rarely reported. We conducted this study to explore whether patients in ordinary condition suffered from kidney injury during the course of COVID-19 and to find out a proper indicator for detecting kidney injury in COVID-19 patients.
Recent Advancements Involving Immunoliposomes to Target Breast Cancer
Breast cancer is caused by genetic abnormalities resulting in uncontrolled growth of breast cells, and is the most commonly diagnosed cancer amongst women. The clinical use of liposomal-based drugs to treat solid tumors such as breast cancer has been shown to improve the overall pharmacological properties of otherwise “unencapsulated” cytotoxic agents.
Pulmonary Adenocarcinoma Transforming into Small Cell Carcinoma: An Extreme Rarity
Primary small cell lung cancer (SCLC) showing epidermal growth factor receptor (EGFR) mutation is extremely rare. Transformation into SCLC has been reported as an evolution of lung adenocarcinoma acquiring resistance to EGFR tyrosine kinase inhibitors (TKI) and is considered to be a rare resistance mechanism of EGFR-TKI therapy.
Liquid Biopsy in Advanced Gastric Malignancy and Molecular Targeted Therapy; a Case Report and Update Pertaining Anti HER2-Neu Therapy
Human epidermal growth factor receptor 2 (HER2) is responsible for the pathogenesis and poor outcomes of several types of cancers, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs on the other hand, such as trastuzumab, prolong overall survival and progression-free survival in HER2-positive gastric cancer. The purpose of the case report is to evaluate the impact of delivering trastuzumab in advanced gastric cancer with concomitant HER2 mutation and amplification.
The Prevalence of Obesity among Subjects with Chronic Kidney Disease – Cross Sectional Study of Sri Lanka Population
The burden of chronic kidney disease (CKD) is growing rapidly around the world, particularly in Asia. Over the last two decades Sri Lanka has experienced an epidemic of CKD, especially in the “Mahaweli” river basin in North Central region of the island that was not attributable to conventional risk factors - hence widely termed “CKD-unknown”.
Phase II Trial of Lower Dose Bevacizumab and Irinotecan in Relapsed High Grade Gliomas
Relapsed high-grade gliomas (HGG) respond poorly to known chemotherapeutic agents with a median survival of 3 to 6 months. Several phase II trials of Bevacizumab for salvage therapy, reported excellent response rates. The optimal dose of Bevacizumab in GBM has not been defined to date. We performed a prospective phase II trial of bevacizumab using 5 mg/kg every 2 weeks.
Drug Tolerability and Outcomes in Kidney Transplant Recipients Treated with Two Formulations of Mycophenolic Acid
Mycophenolic Acid (MPA) is one of the most widely used immunosuppressive agents in kidney transplantation. This study was designed to compare the safety, tolerability and efficacy of two formulations of mycophenolic acid, Mycophenolate Mofetil (MMF) and Enteric-Coated Mycophenolate Sodium (EC-MPS), in renal transplant recipients.
Editorial Board Members Related to eGFR
AMY H. TANG
Associate Professor
Department of Microbiology and Molecular Cell Biology
Eastern Virginia Medical School
United States
Department of Microbiology and Molecular Cell Biology
Eastern Virginia Medical School
United States
